This downturn is attributed to disappointing clinical trial results for some of its drugs and concerns over potential tariffs affecting Denmark. Additionally, competition from Eli Lilly's successful weight-loss drug trials has impacted investor confidence.
Despite these challenges, analysts note that Novo Nordisk maintains strong fundamentals and a positive long-term outlook, particularly in its core areas of diabetes and obesity treatments.
Despite these challenges, analysts note that Novo Nordisk maintains strong fundamentals and a positive long-term outlook, particularly in its core areas of diabetes and obesity treatments.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。